Signal Pharma

Signal Pharma is a business angel-funded joint venture from the Universities of Aberdeen and Toronto, founded in 2013, focussing on the discovery and preclinical development of drugs for the treatment of diseases which are not adequately served by current therapies. These programmes include novel approaches to the treatment of diastolic heart failure, angina, cancer, neuropathic pain, inflammatory pain and type 2 diabetes.